Aeolus Pharmaceuticals, Inc.
AOLS
Rank in Stocks
#35176
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the... Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pulmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Share Price
$0.000001
Last synced: 2026-11-10
Market Cap
$152.09
Change (1 day)
-99.00%
Change (1 year)
-99.00%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Aeolus Pharmaceuticals, Inc. (AOLS)
Category
Healthcare
Operating Margin for Aeolus Pharmaceuticals, Inc. (AOLS)
Operating Margin as of November 2026 TTM: -157.66%
According to Aeolus Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is -157.66%. At the end of 2016 the company had an operating margin of -157.66%.
Operating Margin history for Aeolus Pharmaceuticals, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -157.66% | 0.00% |
| 2016 | -157.66% | 86.78% |
| 2015 | -84.41% | 10,069.88% |
| 2014 | -0.83% | -98.79% |
| 2013 | -68.69% | 111.29% |
| 2012 | -32.51% | -59.83% |
| 2011 | -80.94% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | -100.00% |
| 2006 | -6,091.30% | 121.28% |
| 2005 | -2,752.78% | -29.90% |
| 2004 | -3,926.89% | 0.00% |
| 2003 | 0.00% | -100.00% |
| 2002 | -7,796.51% | -67.49% |
| 2001 | -23,984.09% | 136.11% |
| 2000 | -10,158.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -100.12% |
DE
|
|
| 19.68% | -100.12% |
DE
|
|
| 13.26% | -100.08% |
JP
|
|
| 17.08% | -100.11% |
CH
|
|
| 14.92% | -100.09% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Aeolus Pharmaceuticals, Inc.'s operating margin
What is Aeolus Pharmaceuticals, Inc.'s operating margin?
Aeolus Pharmaceuticals, Inc.'s operating margin is -157.66%, as of Nov 2026.
What was Aeolus Pharmaceuticals, Inc.'s operating margin in 2016?
In 2016, Aeolus Pharmaceuticals, Inc.'s operating margin was -157.66%, compared with -84.41% in 2015.
How has Aeolus Pharmaceuticals, Inc.'s operating margin changed since 2011?
From 2011 to 2016, Aeolus Pharmaceuticals, Inc.'s operating margin was highest in 2014 (-0.83%) and lowest in 2016 (-157.66%).
How does Aeolus Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Aeolus Pharmaceuticals, Inc.'s operating margin (-157.66%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.